Latest News

Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.

The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.

Researchers tested the therapy through the MATCH clinical trial, which involved 50 patients with advanced liver cirrhosis.

Edge Growth, in partnership with FNB’s Vumela Fund, backed Mia Healthcare at a pivotal stage of its development, reinforcing investor confidence in its business model and growth trajectory.

The deal gives Olympus access to BioProtect’s commercially available implant system designed to protect healthy tissue during radiation therapy.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.

The project is supported by the Ministry of Health and Social Protection together with the National Health Institute (Instituto Nacional de Salud), which will coordinate regulatory oversight and public health integration.

The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.

Sentante’s platform enables clinicians to perform endovascular procedures remotely through a teleoperated workstation equipped with haptic feedback controls and multiple operating room displays.